The PANACEA trial revealed that 15% of trastuzumab-resistant HER2-positive breast cancer patients harboring PD-L1-positive tumors elicited a partial response when treated with pembrolizumab plus trastuzumab (14). Here, ERBB2 is linked to breast carcinoma.